Posted on September 27, 2023 by Aldevron
VLOG: mRNA Sequence-to-Vial
Sequence-to-vial doesn’t happen overnight—it requires scientific and engineering expertise, manufacturing proficiency and deep partnerships, which is why it’s a top unmet need for biopharma clients. But it’s also the type of challenge Aldevron embraces.
As we mark our 25th anniversary of advancing every day and never standing still, Aldevron is proud to partner with our Danaher sister companies Cytiva and Precision NanoSystems Inc (PNI), to walk alongside our clients at each stage, from master cell bank to filled finish product.
Hear from our leaders in nucleic acids, RNA client services, manufacturing, and operations on how we developed a reputation as a leader in drug development and where we’ll go next with our clients to help patients in a new way.
MORE FROM THE ADVANCING EVERY DAY BLOG
The Future of RNA: A World of Opportunity
Aldevron’s history has been shaped by the company’s ability to imagine the future of possibilities in medicine and develop the products and services to help drive those visions forward. - Venkata Indurthi
Why Our Work Matters at Aldevron
Regardless of whether our associates are operating bioreactors, developing software, analyzing markets or fulfilling the multitude of other technical jobs we do here, what really drives them is improving the lives of patients. - Sharon King
The Year of the Client
Imagine a world without disease. Since 1998, Aldevron has partnered with pioneers in cell and gene therapy to help make this dream a reality. We have seen incredible advancements the past 25 years, and we are proud of the role we’ve played in supporting these efforts. Like our clients however, we can never stand still. Every day brings new ideas, new opportunities, new challenges to solve. This is what Advancing Every Day means to me – disrupting the status quo, and finding new ways to serve the market in this rapidly evolving space. - Jennifer Meade
